Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanomaSeptember 11, 2017Immuno-oncologyMelanoma
Pembrolizumab, nivolumab linked to 3% rate of neurologic eventsSeptember 5, 2017Immuno-oncologyPatient & Survivor CareMelanomaLung CancerRenal Cell CarcinomaHead & Neck/Thyroid CancersNeuro-oncology
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastasesJune 12, 2017MelanomaImmuno-oncologyImmunotherapyCNS/Brain Cancer
TRK inhibitor shows ‘striking’ activity, durability across diverse adult and pediatric cancersJune 5, 2017Sarcoma & GISTMelanomaGastroenterologyRare DiseasesGastrointestinal Cancer
Immune-agonist combo has activity against several tumor typesJune 5, 2017Immuno-oncologyImmunotherapyBreast CancerMelanomaRenal Cell CarcinomaGynecologic CancerGenitourinary Cancer
How to best evaluate children’s melanocytic lesions for melanomaJune 1, 2017PediatricsPreventive CareMelanoma
SLE linked to subsequent risk of malignant melanomaMay 11, 2017MelanomaPreventive CareImmuno-oncology
Study finds psoriasis link to melanoma and hematologic cancersApril 20, 2017MelanomaLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Get ready for cancer immunotherapy-induced rheumatic diseasesApril 3, 2017ImmunotherapyMelanomaImmuno-oncology
